Eli Lilly's retatrutide, a new weight-loss drug that works three different ways, helped people lose an average of 70 pounds in a big Phase 3 trial. Nearly half of patients lost at least 30% of their body weight, which is as much as people usually lose from weight-loss surgery.

• •Retatrutide is described as a triple agonist in a pivotal Phase 3 obesity trial
• •Average weight loss was approximately 70 pounds in the trial
• •Nearly half of patients lost at least 30% of body weight

Novo Nordisk's pill versions of semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) are now available on Amazon with same-day delivery. This expands how patients can buy these drugs, moving beyond traditional pharmacies.

• •Novo's oral Ozempic and Wegovy pills are now on Amazon
• •Amazon offers same-day delivery for the pills
• •Move expands access beyond traditional pharmacies

Amazon and Novo Nordisk teamed up to deliver the Ozempic pill version on the same day in some areas. This deal makes it easier for people to get the weight-loss drug without waiting.

• •Amazon will deliver Novo Nordisk's Ozempic pill same-day in some areas
• •Deal targets faster access to the oral version of semaglutide

Amazon Pharmacy now delivers semaglutide (Ozempic) pills and lets customers pick them up at offices. This makes the weight-loss drug easier to get through a major online retailer.

• •Amazon Pharmacy now delivers semaglutide (Ozempic) pills
• •Customers can also pick up the drug at Amazon offices

Eli Lilly's obesity pill reached 7,000 prescriptions in its fourth week on the market. The number suggests a slow start compared to competing weight-loss drugs.

• •Lilly's obesity pill hit 7,000 prescriptions in its fourth week on the market
• •Uptake looks slow versus other weight-loss drugs

Torrent Pharmaceuticals sold 2 million dollars worth of generic semaglutide in India, becoming an early leader in the market for the copied version of the weight-loss drug. The company is one of the first to offer an affordable version of semaglutide in India.

• •Torrent Pharma sold $2 million of generic semaglutide in India
• •Torrent is one of the first to offer a low-cost copy in India

Amazon is now offering semaglutide (Ozempic) through self-service kiosks and same-day delivery. This move could change how people buy weight-loss drugs and shake up traditional pharmacy businesses.

• •Amazon now sells Ozempic through self-service kiosks
• •Amazon is offering same-day delivery for semaglutide
• •Move targets traditional pharmacy weight-loss drug sales

• •Amazon will add Novo's Ozempic tablet to its product lineup

Novo Nordisk's oral version of Wegovy (semaglutide pill) sold twice as much as Wall Street expected in the first quarter of 2026. The strong sales helped lift the company's stock price.

• •Oral Wegovy sales doubled Wall Street estimates in Q1 2026
• •Novo Nordisk stock recovered on the results

Amazon is putting Ozempic into its pharmacy kiosks and planning to deliver it the same day customers order. This makes the weight-loss drug easier to get through Amazon's pharmacy service.

• •Amazon is adding Ozempic to its pharmacy kiosks
• •Amazon plans same-day delivery for the drug

• •Novo Nordisk shares rose 9.2%
• •Move tied to momentum around the Wegovy pill

Amazon Pharmacy will now stock Novo Nordisk's Ozempic pill form and deliver it the same day. This makes the weight-loss drug easier to buy without a trip to a physical pharmacy.

• •Amazon Pharmacy will stock Novo Nordisk's Ozempic pill form
• •Same-day delivery offered to patients

Medicare will let seniors buy semaglutide (a weight-loss drug) for $50 a month starting soon. This price cap makes the drug much cheaper than the typical cost and could help more people afford it.

• •Medicare will offer semaglutide for $50 per month
• •The price cap targets seniors on Medicare
• •Semaglutide is used for weight loss

• •Amazon Pharmacy plans to offer a new Ozempic pill from Novo Nordisk

Amazon will start selling Novo Nordisk's Ozempic pill (the tablet form of semaglutide) with same-day delivery and through kiosks. This makes the weight-loss drug easier for patients to get quickly without visiting a traditional pharmacy.

• •Amazon will sell Novo Nordisk's Ozempic pill with same-day delivery
• •The drug will also be available through kiosks
• •Ozempic pill is the tablet form of semaglutide

Amazon will sell semaglutide (Ozempic) pills at its U.S. kiosks and deliver them the same day. This expands where people can buy the weight-loss drug beyond traditional pharmacies.

• •Amazon will sell Ozempic pills at its US kiosks
• •Buyers can get same-day delivery
• •The move expands access beyond traditional pharmacies

Amazon will sell Ozempic (semaglutide), a popular weight-loss drug made by Novo Nordisk, at kiosks in US stores and deliver it the same day. This move makes the expensive drug easier to buy outside of traditional pharmacies.

• •Amazon will sell Ozempic at kiosks in US stores
• •Same-day delivery offered for the drug
• •Ozempic is made by Novo Nordisk

Novo Nordisk raised its financial guidance as demand for the pill version of Wegovy (semaglutide) grows faster than expected. The company's higher outlook may affect how investors value the business.

• •Novo Nordisk raised its financial guidance
• •Demand for oral Wegovy (semaglutide) is growing faster than expected

Novo Nordisk reported strong sales for Wegovy, the pill version of its weight-loss drug. The company also shared plans to launch the medication in more countries soon.

• •Novo Nordisk reported strong Wegovy pill sales in its earnings
• •Novo shared plans to launch Wegovy in more countries

Novo Nordisk beat Wall Street's expectations for revenue and profit in the first quarter of 2026. The company narrowed its full-year earnings forecast.

• •Novo Nordisk beat Wall Street estimates for Q1 2026 revenue and profit
• •Company narrowed its full-year earnings forecast

HYTN Innovations plans to split off its BPC-157 peptide drug business into a separate company. BPC-157 is a peptide being developed as a potential treatment for various conditions.

• •HYTN Innovations plans to spin out its BPC-157 peptide drug business
• •The spin-out would create a separate company focused on BPC-157
• •BPC-157 is being developed as a potential treatment

• •FDA flagged a liver failure report linked to an Eli Lilly GLP-1 drug
• •Lilly stock moved on the news

Novo Nordisk's stock rose after demand for Wegovy pills (the oral version of semaglutide, a weight-loss drug) exceeded what investors expected. Strong pill sales suggest more patients are choosing this form over the injectable version.

• •Novo Nordisk stock rose on strong Wegovy pill demand
• •Oral semaglutide demand beat investor estimates

Novo Nordisk reported better-than-expected earnings and raised its outlook for the rest of the year, driven by strong sales of Wegovy, the pill version of its weight-loss drug semaglutide. The company is seeing more demand than it predicted for the oral form of the medication.

• •Novo Nordisk beat earnings estimates
• •Novo raised its full-year guidance
• •Wegovy pill demand drove the surge

Apotex, a Canadian drugmaker, won approval to make and sell semaglutide in Canada. This adds another manufacturer of the weight-loss drug to the market.

• •Apotex won Canadian approval for semaglutide
• •Adds another semaglutide maker to the Canadian market

Novo Nordisk's weight-loss pill is selling well and pushing the company's stock price up. The article focuses on early sales success for the drug.

• •Novo Nordisk's new weight-loss pill is off to a strong sales start
• •Novo Nordisk stock is rising on the news

Novo Nordisk's Wegovy pill (oral semaglutide) reached 1 million patients and generated $355 million in sales, exceeding company expectations. The oral form has become a major revenue driver alongside the injectable version.

• •Novo's Wegovy pill (oral semaglutide) reached 1 million patients
• •Oral Wegovy generated $355 million in sales
• •Sales beat Novo's own expectations